PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
3 reports, 2 independent
Updated Oct 24
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Two Seas Capital LP invests in PAVmed.1 source
PAVmed filed with the SEC regarding stock acquisition.1 source
PAVmed products require FDA clearance, and the firm is attracting institutional investment interest.1 source
Keep exploring
The entities involved
- FDA
-
Geode Capital Management
American Investment Management firm based in Boston, Massachusetts
Nothing else this week.
Related events
- FDA policy proposal affects the operations of AI, Inc.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- Profusa, Inc. achieved ISO certification, enabling EU market entry, with the standard aligning with FDA QMSR.